Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Interest Expenses (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Interest Expenses for 4 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest Expenses rose 13.02% to $2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $11.1 million, a 9.32% increase, with the full-year FY2024 number at $10.1 million, up 1.86% from a year prior.
  • Interest Expenses was $2.9 million for Q3 2025 at Centessa Pharmaceuticals, roughly flat from $2.9 million in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $2.9 million in Q3 2025 to a low of $1.5 million in Q1 2022.
  • A 4-year average of $2.4 million and a median of $2.5 million in 2024 define the central range for Interest Expenses.
  • Peak YoY movement for Interest Expenses: surged 56.33% in 2023, then decreased 3.54% in 2024.
  • Centessa Pharmaceuticals' Interest Expenses stood at $2.2 million in 2022, then increased by 16.71% to $2.6 million in 2023, then fell by 3.54% to $2.5 million in 2024, then grew by 16.58% to $2.9 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Interest Expenses are $2.9 million (Q3 2025), $2.9 million (Q2 2025), and $2.9 million (Q1 2025).